Using preclinical models and single-cell RNA sequencing, researchers investigated immune and tumor cell adaptations to poly ADP ribosyl polymerase 14 (PARP14) inhibition combined with programmed cell death 1 (PD-1) blockade.
[Journal For Immunotherapy of Cancer]